|
Accession Number
|
ADA567582
|
|
Title
|
Lymphatic Vascular-Based Therapy for IBD.
|
|
Publication Date
|
Jul 2012
|
|
Media Count
|
46p
|
|
Personal Author
|
J. Alexander
|
|
Abstract
|
In the current funding period, we completed studies on the protective effects of adenoviral induced VEGF-D and compared this effect to VEGF-C. These findings were correlated with lymphatic and blood vessel density and support our hypothesis that lymphatic vessel induction is protective in IBD. These findings support lymphatic expansion as a controlling element of blood vessel expansion. We next examined the effects of VEGFR-2 kinase inhibitor, SU1498 and a VEGFR-2 competitor antibody on acute erosive colitis. VEGFR-2 blockade was protective in some phases of colitis and appears to reflect suppression of blood vessels. We also explored whether and how blockade of the pro-lymphangiogenic VEGF receptor, VEGFR-3 (using MAZ51, a VEGFR-3 kinase blocker) would affect acute erosive colitis. We found that VEGFR-3 blockade lead to significant increases in gut tissue injury, particularly when given during the recovery phase of the DSS model. This suggests to us that lymphatics may exert protective influences colitis by hastening recovery from disease rather than preventing its induction.
|
|
Keywords
|
Antibodies
Blood vessels
Colitis
Diseases
Endothelium
Erosion
Induction systems
Kinase blocker
Lymphatic system
Sense organs
Tissues(Biology)
Vascular diseases
Vegfr(Vascular endothelial growth factor receptor)
Vegfr-2 kinase blocker
Wounds and injuries
|
|
|
Source Agency
|
Non Paid ADAS
|
|
NTIS Subject Category
|
57E - Clinical Medicine
|
|
Corporate Author
|
Louisiana State Univ. in Shreveport.
|
|
Document Type
|
Technical report
|
|
Title Note
|
Annual rept. 1 Jul 2011-30 Jun 2012.
|
|
NTIS Issue Number
|
1309
|
|
Contract Number
|
W81XWH-11-1-0577
|
